In particular, said Peters, Sen. Kyrsten Sinema (D-Ariz.) Has not stepped down from his position nearly a month ago in protest of the current drug price changes in the dispute.
“Sénata Sinema has not yet made any request to regulate herbal medicine,” she said in an interview this week. “And I’m trying to get him to come my way because I think openly, I think it would be good to put this issue to rest.”
Cinema spokesman John LaBombard denied Peter Senator’s evidence as a senator, claiming that Cinema was “carefully examining various proposals on the matter” in direct negotiations “for more than $ 300 million.
However, the inability to reach consensus on the issue of drug prices is one of the many remaining obstacles for Democrats as they rush to meet their dead man 31 October. Although a number of other Democrats are known to be reluctant to support the price of drugs, Cinema support is very important in the 50-50 Senate. In order to achieve success, the Biden team continues to be involved in creating the dialogue as they decide how many programs to dive and immerse themselves completely from the program.
For months, the White House had already persuaded Capitol Hill executives to resolve disputes surrounding a key drug law. But in recent weeks, it has been widely reported to moderators in the House and the Senate to seek their support and have emphasized the importance of drug prices in meetings with lawmakers. Peters said the White House caught him on drug charges recently and that “we understand where one is better.”
White House officials have also noted an unsatisfactory agreement between Sen. Bernie Sanders (I-Vt.) And Joe Manchin (DW.Va.) on allowing Medicare to negotiate drug prices, and consider being offered one of the most important package items, according to a well-known leadership concept. Reduction of drug paraphernalia is one of the most recognizable issues in the Biden program and many Democrats see it as the key to their success in mid-2022 and beyond. This is especially true as the first pledge to reduce the age of the Medes and create a designated public insurance policy.
Many lawmakers, including Peters, say they are confident they can find a middle ground between this sweeping HR.3 bill that is favored by the developers which gives Medicare the power to initiate direct contact with pharmaceutical companies, and the proceeds pushed by House centrists that can negotiate less. the prices of that narrow set of drugs. These members say the drafted negotiation bill may be the best they can expect from Democrats’ minority voting and the stigma of opposition from pharmaceutical companies.
“There are still others [drugs] this is always at a high cost, but that’s the way the deal is being negotiated, “said Rep. Susan Wild (D-Penn.), a frontrunner who works on formal negotiations.” I don’t mind if that’s what we want to end. he would probably pay more than the rest of the world for the same drug.
The house is moving forward, outside support groups and Sanders are still tightening the very violent version of the bill and are blaming those who oppose the bird industry of the pharmaceutical industry. People in the camp say they are worried that the low, stable tax rate will fail to generate the federal funds needed to pay for the plans to supplement Medicare, Medicaid and Obamacare programs, and to fail to roll out a campaign that promises to cut patient health costs.
Although negotiations are continuing behind the scenes, lawmakers in both camps say they are not clear on where each other stands.
“I heard it [Sen. Sinema] It is against Medicare to negotiate the price of prescription drugs, ”Sanders told reporters in China, lamenting that he had not heard from him directly from his candidacy. “That’s what I heard. Maybe I made a mistake. ”
Sen. Bob Menendez (DN.J.), an anonymous key to the drug price who once accused his colleagues of using the pharmaceutical industry as a “piggy bank” to pay for other essentials, is also plagued by a lack of focus.
“Negotiations regarding the receipt of a request are two different matters,” he said. “Show me some advice and I’ll tell you how I feel.”
Congress members and foreign diplomats said the recent protests over debt relief and overdue debt relief had cost them dearly and wasted valuable time they could have spent working on drug and other costs of reconciliation legislation.
And with just a few weeks to come to an agreement, the list of unresolved questions surrounding the bill remains long. How many and what types of medications will be under negotiation? Does the government use international or domestic banks for these negotiations, and how will they punish drug companies that refuse to do so? How much money can the government control from companies that raise their prices faster than inflation?
Another key hanging on the payroll is that Democrats can and should use the prices that Medicare negotiates outside of the Court, so that people who get their insurance through work or the private market can benefit.
Many lawmakers and foreign diplomats say the Senate’s parliament is likely to try to increase lower prices for independent insurance schemes, even if his office has not yet formally ruled on the issue. Some are even skeptical that losing any of the commandments would be acceptable.
“History shows that the changes made in Medicare always lead to an independent one,” Senate Chairman Ron Wyden (D-Ore.) Recently told reporters. “Because Medicare is the flagship government program, and if only they knew about it [the lower drug prices], they will continue to cling to it. ”
Hanging on to every controversy over prescription is a prospect of failure and what it means for both the Democratic Party and the big bill itself. Some in the party fear that it may be an attempt to cause serious harm, for example, if it promises to reduce the price of medicines on board but leaves most of the country registered as an independent insurer.
“I don’t think it will be popular to tell voters: ‘I’m sorry, you’re too young to get cheap medicine,'” a lawyer who knew how to communicate told POLITICO.
Sanders agreed, telling POLITICO Democrats should continue to fight for the law to be included even if it is in danger of being abolished by parliament, rather than abolished.
Democrats are also warning that if lawmakers change the law on drug overdose, it will force them to make more painful sacrifices elsewhere.
“HR.3 came with some money,” said Representative Peter Welch (D-Vt.). “What if, in the short run, that money will be cut in half? This has serious implications for treatment, and the members may become irritated. For each action there is an effect on the catch. ”